Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

associated with voluntary field corrections for a portion of its installed base of AVEA® ventilators. While the company is in the process of remediating the affected ventilators, it continues to manufacture and sell its AVEA ventilator products.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D) and restructuring and acquisition integration charges totaled $319 million, or 38 percent of total revenue. Excluding $11 million of nonrecurring items, adjusted operating expenses totaled $308 million, or 36 percent of total revenue. Adjusted SG&A expenses were $269 million and R&D investments totaled $39 million.

New Reporting SegmentsIn July 2011, the company realigned its businesses under two new global operating segments named Medical Systems and Procedural Solutions. Beginning with the first quarter of fiscal 2012, the company also made a determination to realign its reportable segments with the new operating segments. Accordingly, the company is reporting results under these two segments, which are replacing the Critical Care Technologies and Medical Technologies and Services segments under which the company had previously reported. The Medical Systems segment includes the company's Dispensing Technologies, Infusion Systems and Respiratory Technologies business lines. The Procedural Solutions segment includes the company's Infection Prevention, Medical Specialties and Specialty Disposables business lines. The company has separately provided summary historical financial data for the new reportable segments in a report on Form 8-K filed with the Securities and Exchange Commission on Nov. 2, 2011.

Medical SystemsRevenue for the Medical Systems segment increased 9 percent on a reported basis to $509 million, or 7 percent on a constant currency basis, driven by Dispensing Technologies and Infusion Systems sales. Sales in the company's Dispensing Technologies
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ... and,Trademark office has issued a patent for ... development. The newly issued patent, U.S. Patent,# ... matter of PX-867,and pharmaceutical preparations containing PX-867., ...
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Resubmit With New Data from Ongoing Studies, CAMBRIDGE, ... today announced the withdrawal of the European application,to extend ... elderly patients with acute myeloid leukemia (AML). This,application and ... by Bioenvision,Ltd. before the company was acquired by Genzyme ...
Cached Biology Technology:Oncothyreon announces issuance of patent for PX-867 2Oncothyreon announces issuance of patent for PX-867 33SBio Inc. Approves Share Repurchase Program 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 3
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... the possible inventory of molecules available to the ... research professor at Arizona State University, found that ... blazing fireball over California last year, contains organic ... findings suggest a far greater availability of extraterrestrial ...
... of Pharmaceutical Scientists (AAPS) WHAT: ... share the latest groundbreaking scientific discoveries and industry developments ... event will bring together more than 8,000 scientists, business ... initiatives underway aimed at improving global health through advances ...
... have discovered a new defense mechanism that the immune ... how a novel protein unexpectedly activates an immune response ... get rid of tumour cells. This research was done ... July 2013 in Nature Immunology ., 2. The immune ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Novel mechanism discovered in first line of immune defense 2
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
A substrate for all AChE-based EIA kits....
... Degranulation, the secretion of cytoplasmic granules, ... inflammatory response of leukocytes (e.g. basophils, ... addition to histamine, these secretory granules ... cytokines, chemokines, and many proteases (Hallgren, ...
... AGI provides both long and short-term enriched ... animals in both quarantine and non-quarantine settings ... are also available utilizing our state-of-the-art social ... is equipped with on site CDC quarantine ...
Biology Products: